Spire Wealth Management’s Verrica Pharmaceuticals VRCA Stock Holding History

Spire Wealth Management’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-568	Closed	-$2.5K	–	2580
2025 Q1	$2.5K	Buy	568 +3	+0.5%	+$19	﹤0.01%	2234
2024 Q4	$3.96K	Hold	565	–	–	﹤0.01%	2107
2024 Q3	$8.19K	Hold	565	–	–	﹤0.01%	1693
2024 Q2	$41.2K	Hold	565	–	–	﹤0.01%	1180
2024 Q1	$33.4K	Hold	565	–	–	﹤0.01%	1352
2023 Q4	$33.4K	Buy	565 +78	+16%	+$3.21K	﹤0.01%	1340
2023 Q3	$18.9K	Buy	487 +104	+27%	+$5.29K	﹤0.01%	1527
2023 Q2	$22.1K	Hold	383	–	–	﹤0.01%	1554
2023 Q1	$24.9K	Hold	383	–	–	﹤0.01%	1530
2022 Q4	$11K	Buy	+383	New	+$10.2K	﹤0.01%	1588
2022 Q3	–	Sell	-383	Closed	-$7K	–	2618
2022 Q2	$7K	Hold	383	–	–	﹤0.01%	2051
2022 Q1	$31K	Hold	383	–	–	﹤0.01%	1635
2021 Q4	$35K	Hold	383	–	–	﹤0.01%	1893
2021 Q3	$48K	Buy	383 +30	+8%	+$3.36K	﹤0.01%	1495
2021 Q2	$40K	Hold	353	–	–	﹤0.01%	1584
2021 Q1	$53K	Buy	+353	New	+$48.8K	﹤0.01%	1699

Other funds holding VRCA

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sovran Advisors San Diego, California $1.34B AUM 21.63% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Spire Wealth Management's VRCA Position: Q2 2025 in Review

Spire Wealth Management sold out of Verrica Pharmaceuticals (VRCA) in Q2 2025, closing a stake of 568 shares — an estimated $2.5K sold.

Spire Wealth Management first reported a position in VRCA in Q1 2021 and held it in 16 quarters. The position peaked at $53K in Q1 2021. 58 funds tracked by Wall St. Rank hold VRCA as of Q2 2025.

Spire Wealth Management reported no remaining Verrica Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Spire Wealth Management sold 568 Verrica Pharmaceuticals shares in Q2 2025, an estimated $2.5K.
Spire Wealth Management first reported a position in Verrica Pharmaceuticals in Q1 2021 and held it in 16 quarters.
Spire Wealth Management's Verrica Pharmaceuticals position peaked at $53K in Q1 2021.
58 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2025.

Based on Spire Wealth Management's 13F filing for Q2 2025, filed 4 Aug 2025.